BioOutsource and Cellca Services Now Available on Sartorius.com
From Cell Line Development to Lot Release Testing: The Complete Solution for Your Drug Development Journey
In 2015, Sartorius acquired BioOutsource and Cellca, two companies offering services to support bioprocessing in the pharmaceutical industry. These acquisitions have significantly expanded our portfolio of process development and testing solutions, allowing us to provide an industry-leading support service to our customers.
Cellca has long delivered comprehensive cell line development services in fully compliant facilities. Specializing in commercial-scale biologics production in mammalian cells, Cellca is known for its proprietary expression platform, Cellca CHO, an industry-leading host cell/expression vector system for efficient protein production.
BioOutsource offers comprehensive biologics testing, with early success in providing analysis and support for biosimilar development followed by expansion into the new biological entity (NBE) space. BioOutsource also provides comprehensive cell line characterization, cell bank manufacturing services, and a broad range of biosafety testing. Their expertise in assay development and optimization has enabled the creation of a range of platform methodologies facilitating the quick development of critical bioassays as well as off-the-shelf assays designed to support biosimilar comparability studies.
These acquisitions have provided Sartorius with the advanced knowledge and experience required to deliver solutions that support cell line and process development. Sartorius can now provide you with a complete set of solutions to accelerate the approval of your biologic.
Explore Our Growing Portfolio
Evolution of BioOutsource and Cellca
BioOutsource was founded in Glasgow, UK, in 2007 as a leading provider of contract testing services to the global biopharmaceutical industry. BioOutsource had particular success and growth in the biosimilar testing market.
In 2015, BioOutsource was acquired by Sartorius. We opened a new bioanalytical and biosafety testing laboratory in the major biotech hub of Boston, US, in 2016.
We are fully cGMP, GLP and GCP accredited and provide contract testing services to assess the quality and safety of biologic drugs and vaccines. Continued expansion of our overall biologics service offering includes chemistry testing services (2017), cell bank manufacturing (2019), and NBE Product Characterization (2019).
Cellca was founded in 2005 as a cell line and process development service provider. Cellca established a unique technology platform, the Cellca CHO Expression Platform, one of the most competitive systems available for protein expression.
In 2015, Cellca was acquired by Sartorius. Towards the end of 2019, Cellca moved into a 6,000 square meters purpose-built site at Ulm's Science Park III at Eselsberg.
Cell Culture Technology Center | Testing Facilities
Bioanalytics | Biosafety & Characterization Testing
Bioanalytics | Testing Facilities